Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.
Jason Brayer, MD, PhD
Advertisement
Articles by Jason Brayer, MD, PhD
Jason Brayer, MD, PhD, discusses the emergence of bispecific T-cell engagers and bispecific antibodies in multiple myeloma.
Jason Brayer, MD, PhD, discusses bispecific antibodies and T-cell engagers as alternative options to CAR T-cell therapy in patients with multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5